FDA 483 - Jawad A. Qureshi MD - October 21, 2020

An FDA inspection of Jawad A. Qureshi MD in Grapevine, TX, revealed a significant deviation from the investigational plan during a clinical trial. The firm incorrectly administered investigational product to a study subject, necessitating an unscheduled follow-up visit. This indicates a failure to conduct the investigation in accordance with the signed statement of investigator and the approved plan.